Triple Agonist 60mg — Verification Report
From Phase One Labz · Lot mfg726 · Tested August 2026
VialTalk
Triple Agonist 60mg
Phase One Labz
Score
103
Grade
A++
Superlative
Cap color: Unresolved(not recorded; the report and the submitter did not confirm it)
Lot mfg726
Tested August 2026
Report ID
b7328473
Test
Method
Result
Status
PurityFull credit
HPLC
99.94%
Full credit
IdentityStrong
HPLC retention time
Consistent
Strong
ContentFull credit
Gravimetric vs label claim · tested weight disclosed and verified
60 mg labeled · 63.72 mg tested
Full credit
EndotoxinFull credit
USP <85> compendial
0.066 EU/mL
Full credit
Heavy metalsFull credit
ICP-MS
Screened
Full credit
SterilityPartial
PCR / DNA microarray
Screened
Partial
Batch conformityNot submitted
Not tested
Not tested
Not submitted
Additional screens, not scoredFentanyl screen
Verified against the submitted certificate. VialTalk received this vendor's certificate, checked each test against the reported method, and scored it under a published methodology. Tests the vendor did not submit are listed above rather than omitted. Scores above 100 reflect laboratory credibility weighting.
This report is issued by VialTalk. It is not a laboratory certificate.Scoring methodology →
Canonical source: https://vialtalk.com/vendors/phase-one-labz/coas/b7328473-a97e-4556-b6e2-b4927ce0cb9f